专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160367564A1 Pharmaceutical Compound 有权
公开(公告)号：US20160367564A1
公开(公告)日：2016-12-22
申请号：US15100494
申请日：2014-12-02
申请人： IOMET PHARMA LTD
发明人： Phillip Martin Cowley , Alan Wise , Margaret Huggett
IPC分类号： A61K31/551 , C07D401/04 , A61K31/454 , C07D401/14 , C07D471/04 , A61K31/4545 , A61K31/4439 , C07D413/14 , C07D409/14 , A61K31/444 , C07D405/14 , A61K31/4725 , C07D209/40 , A61K31/496 , A61K31/498 , C07D403/04 , A61K31/404 , C07D471/10 , A61K31/435 , C07D401/06 , C07D209/20 , C07D403/06 , A61K31/55 , A61K31/506 , C07D487/04 , A61K31/4985 , A61K31/5377 , A61K31/497 , C07D513/04 , A61K45/06
CPC分类号： A61K31/551 , A61K31/404 , A61K31/435 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D209/20 , C07D209/34 , C07D209/40 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D513/04
摘要： Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X2, X4, X10, and X11 may be the same or different and each is independently selected from C and N; X1, X3, X5, X6, X7, X8, and X9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X4 with the carbon atoms either side of X2 are single bonds, and are only present when X2 is absent, X3 is absent and X4 is C, and when these bonds are present the ring carbons on each side of X2 are not directly bonded to each other; each R1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R1 groups present is such that the valency of X1 is maintained; each R12, R13, R13′, R14, R15 and R15′ may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R16 groups present is such that the valency of X2 is maintained; each R17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R17 groups present is such that the valency of X3 is maintained; each R2, R3, R4, and R5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X6, X7, X8, and X9 are maintained; each R7, R8 and R9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X10, X11, and X5 are maintained; and R6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C1-C6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.

2. 发明申请

US20200230117A1 NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE 审中-公开
公开(公告)号：US20200230117A1
公开(公告)日：2020-07-23
申请号：US16088873
申请日：2017-04-24
申请人： Phillip M. COWLEY , Meredeth Ann MCGOWAN , Thomas J. BROWN , WISE Alan , Hua ZHOU , Yongxin HAN , Kun LIU , Qinglin PU , Hongjun ZHANG , IOMet Pharma Ltd.
发明人： Phillip M. Cowley , Meredeth Ann McGowan , Thomas J. Brown , Yongxin Han , Kun Liu , Qinglin Pu , Alan Wise , Hongjun Zhang , Hua Zhou
IPC分类号： A61K31/438 , C07D519/00
摘要： Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.

3. 发明授权

US10287252B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase 有权
公开(公告)号：US10287252B2
公开(公告)日：2019-05-14
申请号：US15524148
申请日：2015-11-02
申请人： IOmet Pharma Ltd.
发明人： Phillip M. Cowley , Alan Wise , Susan Davis , Margaret Huggett , Michael Kiczun
IPC分类号： C07D237/28 , A61K31/472 , A61K31/4725 , A61K31/502 , A61K45/06 , C07D217/02 , C07D405/12 , C07D409/12 , C07D413/12
摘要： Provided is a compound for use in medicine for inhibiting tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO), which compound comprises formula (I) wherein X1, X2, and X7, may be the same or different and each is independently selected from C and N; X3, X4, X5, and X6 may be the same or different and each is independently selected from C, N, O and S wherein when X3 is N it has a double bond and wherein when X6 is N it has a double bond; the dotted line is a bond which may be present or absent; R1, R2, R3, R4, R5, R6, and R7 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that at least one of R2, R3, R4 and R6 comprises a group Y; and provided that the number of R1, R2, R3, R4, R5, R6, and R7 groups present is such that the respective valencies of X1, X2, X3, X4, X5, X6, and X7 are maintained; and wherein Y is a group having a formula selected from (II), (III), (IV), (V) wherein L may be present or absent, and may be a substituted or unsubstituted organic linking group, and R31 and R32 may be the same or different and are selected from H and a substituted or unsubstituted organic group, X8 is selected from C and N, and each R313 may be the same or different and is selected from H and a substituted or unsubstituted organic group.

4. 发明授权

US11096930B2 Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase 有权
公开(公告)号：US11096930B2
公开(公告)日：2021-08-24
申请号：US16088873
申请日：2017-04-24
申请人： IOMet Pharma Ltd.
发明人： Phillip M. Cowley , Meredeth Ann McGowan , Thomas J. Brown , Yongxin Han , Kun Liu , Qinglin Pu , Alan Wise , Hongjun Zhang , Hua Zhou
IPC分类号： C07D519/00 , A61K31/438
摘要： Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.

5. 发明申请

US20200172492A1 PHARMACEUTICAL COMPOUND 审中-公开
公开(公告)号：US20200172492A1
公开(公告)日：2020-06-04
申请号：US16780349
申请日：2020-02-03
申请人： IOmet Pharma Ltd.
发明人： Phillip M. Cowley , Alan Wise , Susan Davis , Michael Kiczun
IPC分类号： C07D231/56 , A61K31/416 , A61K31/454 , A61K31/496 , C07D401/04 , C07D403/04 , C07D471/08 , C07D471/10 , A61K31/445 , A61K31/439 , C07D417/12 , A61K31/4523 , A61K31/4985 , A61K31/4995 , C07D498/08 , C07D498/04 , C07D487/04 , A61K31/438 , A61K31/499 , C07D471/04 , C07D498/10 , C07D405/06 , C07D401/14 , C07D261/20 , C07D403/14 , C07D403/12 , C07D417/14 , A61K31/435 , A61K31/551 , A61K45/06
摘要： Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises formula (I) wherein X1, and X2 may be the same or different and each is independently selected from C, N, O and S; X3, X4, X5, and X6 may be the same or different and each is independently selected from C and N; each bond represented by a dotted line may be present or absent, provided that at least one such bond is present; R1, R2, R3, R4, R5 and R6 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R1, R2, R3, R4, R5 and R6 groups present is such that the respective valencies of X1, X2, X3, X4, X5, and X6 are maintained; and wherein at least one of R5 and R6 comprises a group Y, wherein Y is a group having a formula selected from (II), (III), (IV), (V), (VI), (VII) wherein L may be present or absent, and may be a substituted or unsubstituted organic linking group; R31 and R32 may be the same or different and are selected from H and a substituted or unsubstituted organic group; each R34 may be the same or different and is selected from H and a substituted or unsubstituted organic group; R35 is selected from a substituted or unsubstituted alcohol group or ether group; each R36 may be the same or different and is selected from H and a substituted or unsubstituted organic group; X7 may be selected from C and N; X8, X9, X10, X11, X12, X13, X14, X15 and X16 may be the same or different and each is independently selected from C, N, O and S; each bond represented by a dotted line may be present or absent; and each R313 may be the same or different and is selected from H and a substituted or unsubstituted organic group.

6. 发明授权

US10155972B2 Screening method 有权
公开(公告)号：US10155972B2
公开(公告)日：2018-12-18
申请号：US15105615
申请日：2014-12-18
申请人： IOmet Pharma Ltd.
发明人： Bill Hunter , Stuart McElroy , Alan Wise
IPC分类号： C12Q1/26 , C12Q1/48
摘要： Provided is a high-throughput coupled enzyme method of screening for a tryptophan-2,3-dioxygenase (TDO) inhibitor compound and/or an indoleamine-2,3-dioxygenase (IDO) inhibitor compound, which method comprises: (a) reacting tryptophan with isolated IDO and/or isolated TDO in the presence of a test compound to form N-formylkynurenine; (b) reacting N-formylkynurenine from step (a) with isolated kynurenine formamidase to form kynurenine; and (c) detecting the kynurenine produced in step (b) and determining whether the test compound is a TDO and/or an IDO inhibitor compound or not from the presence or absence or quantity of the detected kynurenine, wherein step (a) is conducted in the presence of a reducing system suitable for converting IDO and/or TDO from the Fe3+ to the Fe2+ state, and which does not prevent the formation of kynurenine in step (c).

7. 发明申请

US20180354908A1 PHARMACEUTICAL COMPOUND 审中-公开
公开(公告)号：US20180354908A1
公开(公告)日：2018-12-13
申请号：US15524142
申请日：2015-11-02
申请人： IOmet Pharma Ltd.
发明人： Phillip M. Cowley , Alan Wise , Susan Davis , Michael Kiczun
IPC分类号： C07D231/56 , C07D401/04 , C07D471/08 , C07D471/10 , C07D403/04 , A61K31/496 , A61K31/454 , A61K31/416 , A61K31/551 , A61K31/435 , A61K45/06
摘要： Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises formula (I) wherein X1, and X2 may be the same or different and each is independently selected from C, N, O and S; X3, X4, X5, and X6 may be the same or different and each is independently selected from C and N; each bond represented by a dotted line may be present or absent, provided that at least one such bond is present; R1, R2, R3, R4, R5 and R6 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R1, R2, R3, R4, R5 and R6 groups present is such that the respective valencies of X1, X2, X3, X4, X5, and X6 are maintained; and wherein at least one of R5 and R6 comprises a group Y, wherein Y is a group having a formula selected from (II), (III), (IV), (V), (VI), (VII) wherein L may be present or absent, and may be a substituted or unsubstituted organic linking group; R31 and R32 may be the same or different and are selected from H and a substituted or unsubstituted organic group; each R34 may be the same or different and is selected from H and a substituted or unsubstituted organic group; R35 is selected from a substituted or unsubstituted alcohol group or ether group; each R36 may be the same or different and is selected from H and a substituted or unsubstituted organic group; X7 may be selected from C and N; X8, X9, X10, X11, X12, X13, X14, X15 and X16 may be the same or different and each is independently selected from C, N, O and S; each bond represented by a dotted line may be present or absent; and each R313 may be the same or different and is selected from H and a substituted or unsubstituted organic group.

8. 发明授权

US10047074B2 Pharmaceutical compound 有权
公开(公告)号：US10047074B2
公开(公告)日：2018-08-14
申请号：US15504703
申请日：2015-08-13
申请人： IOmet Pharma Ltd.
发明人： Phillip M. Cowley , Alan Wise , Margaret Huggett
IPC分类号： C07D413/12 , C07D233/88 , C07D257/06 , C07D261/14 , C07D413/04 , A61K31/415 , A61K31/455 , A61K31/4164 , A61K31/4439 , A61K31/454 , C07D261/16 , A61K31/4155 , A61K31/41
摘要： Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula (I): wherein X1 is selected from C and N; X3 and X5 may be the same or different and each is independently selected from C, N, O and S; Y is selected from N and O; Z is selected from C, N and O; each bond represented by a dotted line may independently be a double bond or a single bond, provided that valencies at each ring atom are maintained and provided that the ring Q contains at least one double bond and provided that the atom N has a double bond; R3 and R5 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R3 groups present is such that the valency of X3 is maintained, and the number of R5 groups present is such that the valency of X5 is maintained; each R11 and R12 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R11 and R12 groups present is such that the valency of Z is maintained; R21 is selected from H and a substituted or unsubstituted organic group; R22 may be present or absent and is selected from H and a substituted or unsubstituted organic group; and Cy is a cyclic organic group.

9. 发明授权

US10858319B2 Indole derivatives for use in medicine 有权
公开(公告)号：US10858319B2
公开(公告)日：2020-12-08
申请号：US16190334
申请日：2018-11-14
申请人： IOMet Pharma Ltd.
发明人： Phillip M. Cowley , Alan Wise , Michael Kiczun , Susan Davis
IPC分类号： C07D401/12 , C07D209/42 , A61K45/06 , C07D263/58 , C07D403/12 , C07D405/12 , C07D471/04 , C07D409/12 , C07D405/14 , C07D413/12 , C07D417/12 , A61K31/4155 , A61K31/416 , A61K31/4178 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/475 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/437 , A61K31/4355 , A61K31/424 , A61K31/423 , A61K31/4188 , A61K31/4184 , A61K31/407 , A61K31/405 , A61K31/4045 , A61K31/404
摘要： Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.

10. 发明授权

US10501458B2 Substituted bicyclic fused ring compounds as indoleamine-2,3-dioxygenase inhibitors 有权
公开(公告)号：US10501458B2
公开(公告)日：2019-12-10
申请号：US15738365
申请日：2016-07-01
申请人： Merck Sharp & Dohme Corp. , IOmet Pharma Ltd.
发明人： Phillip M. Cowley , Alan Wise , Thomas J. Brown , Meredeth A. McGowan , Hua Zhou , Yongxin Han
IPC分类号： C07D471/04 , A61K31/4545 , A61K45/06 , A61K31/437 , A61K31/4523 , A61K31/496
CPC分类号： C07D471/04 , A61K31/437 , A61K31/4523 , A61K31/4545 , A61K31/496 , A61K45/06
摘要： Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the general formula (I) detailed within.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式